19:58 , Jul 26, 2019 |  BC Extra  |  Company News

AbbVie’s 2Q previews future growth drivers

New sales figures from AbbVie's 2Q19 earnings report gave investors a glimpse into the launch trajectories of drugs the pharma is relying upon to replace lost sales of Humira after the blockbuster begins to face...
22:53 , Jul 23, 2019 |  BC Extra  |  Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
22:34 , May 14, 2019 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
19:15 , May 10, 2019 |  BioCentury  |  Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
22:56 , Dec 17, 2018 |  BioCentury  |  Politics, Policy & Law

When drugs can’t go generic: Honoring our end of the contract with 'synthetic genericization'

The biopharma industry’s social contract with society relies on the idea that drugs eventually go generic and thereafter remain inexpensive. When that can’t happen, the contract breaks down - but there are ways to fix...
03:14 , Dec 8, 2018 |  BioCentury  |  Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
15:27 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves AbbVie's Orilissa for endometriosis pain

FDA approved Orilissa elagolix from AbbVie Inc. (NYSE:ABBV) for the management of moderate to severe pain associated with endometriosis. AbbVie expects to launch the drug early next month at a wholesale acquisition cost (WAC) of...
16:43 , Jul 24, 2018 |  BC Extra  |  Company News

FDA approves AbbVie's Orilissa for endometriosis pain

FDA approved Orilissa elagolix from AbbVie Inc. (NYSE:ABBV) for the management of moderate to severe pain associated with endometriosis. AbbVie expects to launch the drug early next month at a wholesale acquisition cost (WAC) of...